AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00373-07v1
51/12/4471    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siddiqui, R.
Right arrow Articles by Khan, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siddiqui, R.
Right arrow Articles by Khan, N. A.
Antimicrobial Agents and Chemotherapy, December 2007, p. 4471-4473, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00373-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Effect of Antimicrobial Compounds on Balamuthia mandrillaris Encystment and Human Brain Microvascular Endothelial Cell Cytopathogenicity{triangledown}

Ruqaiyyah Siddiqui,1 Abdul Matin,1 David Warhurst,2 Monique Stins,3 and Naveed Ahmed Khan1*

School of Biological and Chemical Sciences, Birkbeck College,1 London School of Hygiene and Tropical Medicine, University of London, London, England, United Kingdom,2 Pediatric Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland3

Received 20 March 2007/ Returned for modification 20 June 2007/ Accepted 9 September 2007


   ABSTRACT
Top
 ABSTRACT
TEXT
 REFERENCES
 
Cycloheximide, ketoconazole, or preexposure of organisms to cytochalasin D prevented Balamuthia mandrillaris-associated cytopathogenicity in human brain microvascular endothelial cells, which constitute the blood-brain barrier. In an assay for inhibition of cyst production, these three agents prevented the production of cysts, suggesting that the biosynthesis of proteins and ergosterol and the polymerization of actin are important in cytopathogenicity and encystment.


   TEXT
Top
 ABSTRACT
 TEXT
REFERENCES
 
Balamuthia mandrillaris is an emerging protozoan pathogen with the ability to produce central nervous system infections (6, 7, 19). The current treatment regimen involves a mixture of drugs to provide additive or synergistic effects, but even so mortality remains very high (~98%) (4, 19). This may be due to difficulties in diagnosing Balamuthia amoebic encephalitis (BAE), resulting in a delay in the initiation of chemotherapy; poor penetration of antimicrobial compounds across the blood-brain barrier; and perhaps the ability of B. mandrillaris to switch its phenotype into the resistant cyst form. For the latter, it has been shown that B. mandrillaris cysts develop a relatively impermeable triple-walled structure (9, 15). In addition to possible drug resistance, cysts may also reactivate following antimicrobial chemotherapy leading to recurrence of infection. Thus, a complete understanding of B. mandrillaris encystment and identification of compounds that can interfere with the encystment process should be of value in the improved treatment of BAE. Given that B. mandrillaris is a close relative of Acanthamoeba (2), it may contain similar membrane sterols, i.e., ergosterol and its precursor cycloartenol and ergosterol-like sterols (11, 17). This is supported by findings that ketoconazole, a preferential inhibitor of ergosterol biosynthesis (5), exhibits amoebastatic effects on B. mandrillaris in vitro (14) and BAE patients showed some response to this compound (3). Here, we examined the roles of ergosterol biosynthesis, cytoskeletal rearrangements, and protein synthesis in B. mandrillaris encystment and determined whether inhibiting these pathways would block amoeba-mediated cytopathogenicity in cultured human brain microvascular endothelial cells (HBMEC).

B. mandrillaris ATCC 50209, isolated from the brain of a mandrill baboon, was obtained from the American Type Culture Collection and routinely cultured on host cell monolayers as feeder layers as previously described (6). For cytopathogenicity assays, primary HBMEC were isolated from human tissue and grown in RPMI 1640 medium containing 10% fetal bovine serum, 10% NuSerum, 2 mM glutamine, 1 mM pyruvate, penicillin (100 U/ml), streptomycin (100 U/ml), nonessential amino acids, and vitamins as previously described (1, 18).

RPMI 1640 medium induces optimal B. mandrillaris encystment at 37°C. To determine the optimal conditions to induce encystment in B. mandrillaris, various parameters were used. Briefly, B. mandrillaris (>95% trophozoites at a cell density of 0.5 x 105 to 5 x 105/ml) were suspended in RPMI 1640 medium alone or containing glucose-NaCl (to achieve up to 500 mosmol) at temperatures ranging from 4°C to 42°C. Plates were incubated for up to 48 h, followed by the addition of sodium dodecyl sulfate (0.5% final concentration) to lyse the remaining trophozoites. Counts were performed with a hemocytometer, both before and after sodium dodecyl sulfate (SDS) treatment. To quantify encystment, the percentage of B. mandrillaris amoebae that transformed into cysts was determined as follows: % encystment = (no. of amoebae after SDS treatment/no. of amoebae before SDS treatment) x 100. Data are presented as the mean ± the standard error. To determine their viability, cysts prepared in the presence or absence of drugs but prior to SDS treatment were inoculated onto HBMEC monolayers and incubated for up to 7 days and periodically observed for the emergence of trophozoites. Our results demonstrated that B. mandrillaris suspended in RPMI 1640 medium alone at a cell density of 2 x 105/ml and incubated at 37°C for 48 h exhibited optimal encystment (Table 1). Of note, the presence of MgCl2 induced large clustering of amoebae, which presented problems in counting and thus MgCl2 was omitted.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Encystment of B. mandrillaris at 37°C

 
Protein synthesis is crucial in B. mandrillaris encystment and amoeba-mediated cytopathogenicity. The eukaryotic translational inhibitor cycloheximide blocked B. mandrillaris encystment (more than 90%) at micromolar concentrations (Table 1), as measured by increased SDS lability. In addition, flucytosine, which affects RNA and DNA synthesis and inducs abnormal protein synthesis, partially inhibited B. mandrillaris encystment (Table 1), further supporting the cycloheximide findings, while artemisinin, an antimalarial endoperoxide from Artemisia annua (Chinese sweet wormwood) (13), partially inhibited B. mandrillaris encystment (Table 1). In contrast, clindamycin, an inhibitor of bacterial protein synthesis that binds to the 50S subunit and inhibits peptidyl transferase activity, had no significant effect on B. mandrillaris encystment (Table 1).

Next, we determined whether B. mandrillaris-mediated HBMEC death involves protein synthesis. Amoebae were treated with cycloheximide for 45 min in serum-free medium and then added to HBMEC monolayers in the presence of inhibitor in 24-well plates (105 amoebae/well). Plates were incubated at 37°C in a 5% CO2 incubator for up to 24 h. After this incubation, supernatants were collected and cytotoxicity was determined by measuring lactate dehydrogenase release with a cytotoxicity detection kit (Roche Applied Science) as previously described (16). The results revealed that cycloheximide, flucytosine, and artemisinin partially inhibited parasite-mediated HBMEC cytopathogenicity (Table 2). In contrast, clindamycin had no effect on B. mandrillaris-mediated HBMEC cytopathogenicity (Table 2). Of note, 200 µM cycloheximide alone exhibited significant HBMEC cytopathogenicity (data not shown).


View this table:
[in this window]
[in a new window]

  		TABLE 2. Effects of various drugs on B. mandrillaris-mediated cytopathogenicity in HBMEC

 
Both encystment in B. mandrillaris and amoeba-mediated HBMEC cytopathogenicity involve cytoskeletal rearrangements. Given that encystment involves the acquisition of a triple-walled structure, we hypothesized that cytoskeletal rearrangements may play an important role in B. mandrillaris encystment. Encystment assays performed in the presence of cytochalasin D, an inhibitor of actin polymerization, blocked amoeba encystment (Table 1). To determine the role of phagocytosis in amoeba-mediated HBMEC death, parasites were treated with cytochalasin D for 45 min and then cytopathogenicity assays were performed. As shown in Table 2, cytochalasin D partially inhibited B. mandrillaris-mediated HBMEC death, suggesting that B. mandrillaris uses phagocytic processes to produce HBMEC damage. Because host cell destruction is a result of contact (8, 10), the term cytopathogenicity is used. In support, parasite-conditioned medium did not produce HBMEC destruction.

Ergosterol biosynthesis may play an important role in the encystment and cytopathogenicity of B. mandrillaris. Previous studies have shown that ketoconazole has amoebastatic effects on B. mandrillaris (14), suggesting that ergosterol may be an important constituent of amoeba membranes. Here, we observed that cysts developing in the presence of ketoconazole (10 µg/ml) were only partially formed and appeared somewhat hollow. More importantly, these cysts were not viable, as determined by their inoculation on HBMEC monolayers as feeder layers and incubation for up to 7 days (data not shown). These findings led us to conclude that ketoconazole blocked encystment, suggesting a role for ergosterol biosynthesis in amoeba encystment (Table 1). Furthermore, ketoconazole exhibited protective effects against amoeba-mediated HBMEC cytopathogenicity (Table 2). In the presence of ketoconazole (10 µg/ml), the HBMEC monolayers remained intact while lactate dehydrogenase release was minimal. In addition, ketoconazole alone had no significant toxic effects on the host cells (<5%; data not shown).

Ketoconazole is known to interfere with the biosynthesis of ergosterol, which is an important structural component of the membrane, thus leading to defective membranes, increased permeability, and leakage of ions from the cell (12). This is not a surprising finding, given that Balamuthia is a close relative of Acanthamoeba and ergosterol is known to be a major sterol membrane component of Acanthamoeba (11, 17). These studies suggested that the ergosterol biosynthesis pathway may be a potential target in the rational development of therapeutic interventions against B. mandrillaris infections. This is supported by the fact that ergosterol biosynthesis is limited to fungi and protozoa, while human cells contain cholesterol. Further characterization of the ergosterol biosynthesis pathway, including its regulation, may suggest improved combinations of sterol biosynthesis inhibitors to optimize their antiparasitic effects.

In conclusion, these studies suggested that protein synthesis, cytoskeletal rearrangements, and possibly ergosterol biosynthesis are important pathways in B. mandrillaris encystment and that inhibiting these pathways blocked amoeba-mediated cytopathogenicity in cultured primary HBMEC. Future studies of the molecular mechanisms associated with B. mandrillaris encystment should provide insights into the biology of these important organisms that may also be of potential value in the rational development of therapeutic interventions.


   ACKNOWLEDGMENTS
 
This work was supported by grants from the Faculty Research Fund, Central Research Fund, University of London, The Nuffield Foundation, and The Royal Society.


   FOOTNOTES
 
* Corresponding author. Mailing address: School of Biological and Chemical Sciences, Birkbeck College, University of London, London WC1E 7HX, England, United Kingdom. Phone: 44-(0)207-079-0797. Fax: 44-(0)207-631-6246. E-mail: n.khan{at}sbc.bbk.ac.uk Back

{triangledown} Published ahead of print on 17 September 2007. Back


   REFERENCES
Top
 ABSTRACT
 TEXT
 REFERENCES
 

  1. Alsam, S., K. S. Kim, M. Stins, A. O. Rivas, J. Sissons, and N. A. Khan. 2003. Acanthamoeba interactions with human brain microvascular endothelial cells. Microb. Pathog. 35:235-241.[CrossRef][Medline]
  2. Booton, G. C., J. R. Carmichael, G. S. Visvesvara, T. J. Byers, and P. A. Fuerst. 2003. Genotyping of Balamuthia mandrillaris based on nuclear 18S and mitochondrial 16S rRNA genes. Am. J. Trop. Med. Hyg. 68:65-69.[Abstract/Free Full Text]
  3. Denney, C. F., V. J. Iragui, L. D. Uber-Zak, N. C. Karpinski, E. J. Ziegler, G. S. Visvesvara, and S. L. Reed. 1997. Amebic meningoencephalitis caused by Balamuthia mandrillaris: case report and review. Clin. Infect. Dis. 25:1354-1358.[Medline]
  4. Galarza, M., V. Cuccia, F. P. Sosa, and J. A. Monges. 2002. Pediatric granulomatous cerebral amebiasis: a delayed diagnosis. Pediatr. Neurol. 26:153-156.[CrossRef][Medline]
  5. Hankins, E. G., J. R. Gillespie, K. Aikenhead, and F. S. Buckner. 2005. Upregulation of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. Mol. Biochem. Parasitol. 144:68-75.[CrossRef][Medline]
  6. Jayasekera, S., J. Sissons, J. Tucker, C. Rogers, D. Nolder, D. Warhurst, S. Alsam, J. M. L. White, E. M. Higgins, and N. A. Khan. 2004. Post mortem culture of Balamuthia mandrillaris from the brain and cerebrospinal fluid of a case of granulomatous amoebic meningoencephalitis, using human brain microvascular endothelial cells. J. Med. Microbiol. 53:1007-1012.[Abstract/Free Full Text]
  7. Khan, N. A. 2006. Acanthamoeba: biology and increasing importance in human health. FEMS Microbiol. Rev. 30:564-595.[CrossRef][Medline]
  8. Kiderlen, A. F., P. S. Tata, M. Ozel, U. Laube, E. Radam, and H. Schäfer. 2006. Cytopathogenicity of Balamuthia mandrillaris, an opportunistic causative agent of granulomatous amebic encephalitis. J. Eukaryot. Microbiol. 53:456-463.[CrossRef][Medline]
  9. Martinez, A. J., F. L. Schuster, and G. S. Visvesvara. 2001. Balamuthia mandrillaris: its pathogenic potential. J. Eukaryot. Microbiol. 48:6-9.[CrossRef]
  10. Matin, A., M. Stins, K. S. Kim, and N. A. Khan. 2006. Balamuthia mandrillaris exhibits metalloprotease activities. FEMS Immunol. Med. Microbiol. 47:83-91.[CrossRef][Medline]
  11. Raederstorff, D., and M. Rohmer. 1985. Sterol biosynthesis de nova via cycloartenol by the soil amoeba Acanthamoeba polyphaga. Biochem. J. 231:609-615.[Medline]
  12. Sande, M. A., and G. L. Mandell. 1985. Antimicrobial agents: antifungal and antiviral agents, p. 1219-1239. In A. G. Gilman, L. S. Goodman, T. W. Rall, and F. Murad, (ed.), Goodman and Gilman's the pharmacological basis of therapeutics, seventh ed. Macmillan Publishing Co., New York, NY.
  13. Schmuck, G., E. Roehrdanz, R. K. Haynes, and R. Kahl. 2002. Neurotoxic mode of action of artemisinin. Antimicrob. Agents Chemother. 46:821-827.[Abstract/Free Full Text]
  14. Schuster, F. L., and G. S. Visvesvara. 1996. Axenic growth and drug sensitivity studies of Balamuthia mandrillaris, an agent of amebic meningoencephalitis in humans and other animals. J. Clin. Microbiol. 34:385-388.[Abstract]
  15. Schuster, F. L., and G. S. Visvesvara. 2004. Opportunistic amoebae: challenges in prolylaxis and treatment. Drug Resist. Updates 7:41-51.[CrossRef][Medline]
  16. Sissons, J., K. S. Kim, M. Stins, S. Jayasekera, S. Alsam, and N. A. Khan. 2005. Acanthamoeba castellanii induces host cell death via a phosphatidylinositol 3-kinase-dependent mechanism. Infect. Immun. 73:2704-2708.[Abstract/Free Full Text]
  17. Smith, F. R., and E. D. Korn. 1968. 7-Dehydrostigmasterol and ergosterol: the major sterols of an amoeba. J. Lipid Res. 9:405-408.[Abstract]
  18. Stins, M. F., F. Gilles, and K. S. Kim. 1997. Selective expression of adhesion molecules on human brain microvascular endothelial cells. J. Neuroimmunol. 76:81-90.[CrossRef][Medline]
  19. Visvesvara, G. S., H. Moura, and F. L. Schuster. 2007. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol. Med. Microbiol. 50:1-26.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, December 2007, p. 4471-4473, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00373-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00373-07v1
51/12/4471    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siddiqui, R.
Right arrow Articles by Khan, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siddiqui, R.
Right arrow Articles by Khan, N. A.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS